Anti-tumour activity of zinc ionophore pyrithione in human ovarian cancer cells through inhibition of proliferation and migration and promotion of lysosome-mitochondrial apoptosis
Source abstract
Abstract
Zinc pyrithione (ZPT) is widely used as an antimicrobial. Zinc is a necessary trace element of the human whose homeostasis associated with several cancers. However, the anticancer effect of increased Zinc in ovarian cancer is still unclear. This study focussed on the anti-tumour effects of ZPT combined with Zinc in SKOV3 and SKOV3/DDP cells. The cell viability, apoptosis, migration, and invasion assays were detected by CCK-8, flow cytometry, wound healing and transwell assay, respectively. The distribution of Zinc in cells was monitored by staining of Zinc fluorescent dye and lysosome tracker. The changes in lysosomal membrane stability were reflected by acridine orange fluorescence and cathepsin D reposition. Expression of the proteins about invasion and apoptosis was evaluated by western blot. The results indicated that ZPT combined with Zinc could notably reduce cell viability, inhibit migration and invasion in SKOV3 and SKOV3/DDP cells. Besides, ZPT performed as a Zinc carrier targeted lysosomes, caused the increase of its membrane permeability and the release of cathepsin D accompanied by mitochondrial apoptosis in SKOV3/DDP cells. In conclusion, our work suggests that ZPT combined with Zinc could inhibit proliferation, migration, invasion, and promote apoptosis by trigger the lysosome-mitochondrial apoptosis pathway in ovarian carcinoma.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Trace Elements in Health · Cell death mechanisms and regulation · Drug Transport and Resistance Mechanisms
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Radiation and Medical Oncology, Hubei Province Cancer Clinical Study Center, Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University
Department of Traditional Chinese Medicine, Zhongnan Hospital of Wuhan University
Funding
National Natural Science Foundation · Zhongnan Hospital of Wuhan University, Science, Technology and Innovation Seed Fund · Natural Science Foundation of Hubei Province · Scientific Fund of Health Commission of Hubei Province
References (48)
Show source-provided references
1. 10.1038/nrc294610.1038/nrc2946 ↗
2. 10.1053/j.gastro.2017.02.00610.1053/j.gastro.2017.02.006 ↗
3. 10.1038/nrdp.2016.6110.1038/nrdp.2016.61 ↗
4. 10.1080/14728222.2017.126550610.1080/14728222.2017.1265506 ↗
5. 10.1073/pnas.160945011310.1073/pnas.1609450113 ↗
6. 10.1073/pnas.070930710410.1073/pnas.0709307104 ↗
7. 10.1016/0090-8258(89)90053-X10.1016/0090-8258(89)90053-X ↗
8. 10.2174/092986732366616040511154310.2174/0929867323666160405111543 ↗
9. 10.1093/carcin/bgl01210.1093/carcin/bgl012 ↗
10. Liaw KY, Lee PH, Wu FC, et al. Zinc, copper, and superoxide dismutase in hepatocellular carcinoma. Am J Gastroenterol. 1997;92(12):2260–2263.
11. 10.1093/carcin/bgl03410.1093/carcin/bgl034 ↗
12. 10.1039/C8CC00604K10.1039/C8CC00604K ↗
13. 10.1046/j.1467-2494.2003.00183.x10.1046/j.1467-2494.2003.00183.x ↗
14. 10.1016/j.ecoenv.2018.06.02610.1016/j.ecoenv.2018.06.026 ↗
15. 10.1111/j.1365-2133.2012.10863.x10.1111/j.1365-2133.2012.10863.x ↗
16. 10.1002/iub.25310.1002/iub.253 ↗
17. 10.1042/BJ2008142110.1042/BJ20081421 ↗
18. 10.1016/j.tim.2017.04.01010.1016/j.tim.2017.04.010 ↗
19. Yu H, Lou JR, Ding WQ. Clioquinol independently targets NF-kappaB and lysosome pathways in human cancer cells. Anticancer Res. 2010;30(6):2087–2092.
20. 10.1186/s12885-018-4264-210.1186/s12885-018-4264-2 ↗
21. 10.1016/j.ijrobp.2018.07.61710.1016/j.ijrobp.2018.07.617 ↗
22. 10.1038/onc.2008.31010.1038/onc.2008.310 ↗
23. 10.1038/527S217a10.1038/527S217a ↗
24. 10.1016/S0140-6736(16)00631-010.1016/S0140-6736(16)00631-0 ↗
25. 10.1007/s00775-011-0797-410.1007/s00775-011-0797-4 ↗
26. 10.1038/nrurol.2013.4310.1038/nrurol.2013.43 ↗
27. McQuitty JT, Jr., DeWys WD, Monaco L, et al. Inhibition of tumor growth by dietary zinc deficiency. Cancer Res. 1970;30(5):1387–1390.
28. 10.1016/j.semcancer.2015.03.00810.1016/j.semcancer.2015.03.008 ↗
29. 10.1093/clinchem/32.1.10110.1093/clinchem/32.1.101 ↗
30. 10.3390/nu408087510.3390/nu4080875 ↗
31. 10.1007/s00726-010-0689-x10.1007/s00726-010-0689-x ↗
32. 10.1016/j.canlet.2003.09.02910.1016/j.canlet.2003.09.029 ↗
33. 10.1021/acs.nanolett.5b0192610.1021/acs.nanolett.5b01926 ↗
34. 10.1158/2326-6066.CIR-17-046610.1158/2326-6066.CIR-17-0466 ↗
35. 10.1016/j.ccr.2012.12.02010.1016/j.ccr.2012.12.020 ↗
36. 10.1038/sj.onc.120751510.1038/sj.onc.1207515 ↗
37. 10.3109/07388551.2015.101595710.3109/07388551.2015.1015957 ↗
38. 10.1038/nrm297010.1038/nrm2970 ↗
39. 10.1084/jem.2002195210.1084/jem.20021952 ↗
40. 10.1016/j.tiv.2017.08.00610.1016/j.tiv.2017.08.006 ↗
41. 10.2147/DDDT.S8766210.2147/DDDT.S87662 ↗
42. 10.1021/acschembio.8b0006410.1021/acschembio.8b00064 ↗
43. 10.1016/j.metabol.2018.09.00210.1016/j.metabol.2018.09.002 ↗
44. 10.1016/j.bios.2015.10.06110.1016/j.bios.2015.10.061 ↗
45. 10.1016/j.bcp.2014.12.01410.1016/j.bcp.2014.12.014 ↗
46. 10.1126/scisignal.aal416110.1126/scisignal.aal4161 ↗
47. 10.1158/1535-7163.MCT-13-094410.1158/1535-7163.MCT-13-0944 ↗
48. 10.2217/nnm-2017-035910.2217/nnm-2017-0359 ↗